Cargando…

ODP345 Pituitary Metastasis from Clear Cell Renal Cell Carcinoma

A 63-year-old female presented with a two month history of intermittent diplopia and headaches. Her past medical history was relevant for renal carcinoma status post right nephrectomy four years prior, she did not receive any adjuvant therapy. She underwent MRI brain which showed a 2.1×2. 0×1.6 cm s...

Descripción completa

Detalles Bibliográficos
Autores principales: Cristiano, Elizabeth, Pagadala, Prathyusha, Crow, Hanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625792/
http://dx.doi.org/10.1210/jendso/bvac150.1054
_version_ 1784822589767548928
author Cristiano, Elizabeth
Pagadala, Prathyusha
Crow, Hanna
author_facet Cristiano, Elizabeth
Pagadala, Prathyusha
Crow, Hanna
author_sort Cristiano, Elizabeth
collection PubMed
description A 63-year-old female presented with a two month history of intermittent diplopia and headaches. Her past medical history was relevant for renal carcinoma status post right nephrectomy four years prior, she did not receive any adjuvant therapy. She underwent MRI brain which showed a 2.1×2. 0×1.6 cm sellar/suprasellar enhancing mass with mass effect on the optic chiasm and extending into the right cavernous sinus, consistent with pituitary macroadenoma. Visual field testing was also done showing mild bitemporal quadrantanopia. Lab evaluation did not show evidence of pituitary hormone excess or deficiency. Serum sodium was normal, IGF-1 117 ng/ml (reference range 35-201 ng/ml), GH 0.19 ng/ml (0. 01 -3.61 ng/ml), alpha subunit 0.4 ng/ml (<1.8 in postmenopausal females), ACTH 15 pg/ml (7-63 pg/ml), prolactin 20.8 ng/ml (3.3 -26.7 ng/ml), TSH 2.36 MCU/ml (0.35-5 MCU/ml) and FT4 0.9 ng/dl (0.6 -1.6 ng/dl). Neurosurgery evaluated the patient and she underwent transsphenoidal surgery. Her postoperative period was unremarkable without evidence of diabetes insipidus or secondary adrenal insufficiency. Final pathology revealed clear cell lesion/carcinoma consistent with metastatic renal cell carcinoma. Transcription marker testing was positive for SF1, consistent with a gonadotroph pituitary adenoma. Presentation: No date and time listed
format Online
Article
Text
id pubmed-9625792
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96257922022-11-14 ODP345 Pituitary Metastasis from Clear Cell Renal Cell Carcinoma Cristiano, Elizabeth Pagadala, Prathyusha Crow, Hanna J Endocr Soc Neuroendocrinology and Pituitary A 63-year-old female presented with a two month history of intermittent diplopia and headaches. Her past medical history was relevant for renal carcinoma status post right nephrectomy four years prior, she did not receive any adjuvant therapy. She underwent MRI brain which showed a 2.1×2. 0×1.6 cm sellar/suprasellar enhancing mass with mass effect on the optic chiasm and extending into the right cavernous sinus, consistent with pituitary macroadenoma. Visual field testing was also done showing mild bitemporal quadrantanopia. Lab evaluation did not show evidence of pituitary hormone excess or deficiency. Serum sodium was normal, IGF-1 117 ng/ml (reference range 35-201 ng/ml), GH 0.19 ng/ml (0. 01 -3.61 ng/ml), alpha subunit 0.4 ng/ml (<1.8 in postmenopausal females), ACTH 15 pg/ml (7-63 pg/ml), prolactin 20.8 ng/ml (3.3 -26.7 ng/ml), TSH 2.36 MCU/ml (0.35-5 MCU/ml) and FT4 0.9 ng/dl (0.6 -1.6 ng/dl). Neurosurgery evaluated the patient and she underwent transsphenoidal surgery. Her postoperative period was unremarkable without evidence of diabetes insipidus or secondary adrenal insufficiency. Final pathology revealed clear cell lesion/carcinoma consistent with metastatic renal cell carcinoma. Transcription marker testing was positive for SF1, consistent with a gonadotroph pituitary adenoma. Presentation: No date and time listed Oxford University Press 2022-11-01 /pmc/articles/PMC9625792/ http://dx.doi.org/10.1210/jendso/bvac150.1054 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Neuroendocrinology and Pituitary
Cristiano, Elizabeth
Pagadala, Prathyusha
Crow, Hanna
ODP345 Pituitary Metastasis from Clear Cell Renal Cell Carcinoma
title ODP345 Pituitary Metastasis from Clear Cell Renal Cell Carcinoma
title_full ODP345 Pituitary Metastasis from Clear Cell Renal Cell Carcinoma
title_fullStr ODP345 Pituitary Metastasis from Clear Cell Renal Cell Carcinoma
title_full_unstemmed ODP345 Pituitary Metastasis from Clear Cell Renal Cell Carcinoma
title_short ODP345 Pituitary Metastasis from Clear Cell Renal Cell Carcinoma
title_sort odp345 pituitary metastasis from clear cell renal cell carcinoma
topic Neuroendocrinology and Pituitary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625792/
http://dx.doi.org/10.1210/jendso/bvac150.1054
work_keys_str_mv AT cristianoelizabeth odp345pituitarymetastasisfromclearcellrenalcellcarcinoma
AT pagadalaprathyusha odp345pituitarymetastasisfromclearcellrenalcellcarcinoma
AT crowhanna odp345pituitarymetastasisfromclearcellrenalcellcarcinoma